Skip to content
FibonacciAestheticsLog inTry it free

Consent and legal protection

The off-label drug: what the Code of Medical Ethics says and what to write in the clinical record

Off-label use in aesthetic medicine: Article 13 of the Code of Medical Ethics requires justification and written consent. How to record it.

The Fibonacci editorial teamUpdated on 6 min read

A hand opening a medicine box
In this article
  1. What «off-label» means and where the indication is found
  2. What the doctor must say and document
  3. Assessing the effects over time and reporting
  4. Guidelines and good practice
  5. A medical device used outside its intended purpose
  6. How it is recorded, in Fibonacci
  7. A checklist

Using a medicine off-label, that is, for an indication or at a dosage that the summary of product characteristics does not provide for, is permitted by the Code of Medical Ethics under written conditions: tolerability and efficacy must have a scientific basis, the risks must be proportionate to the benefits, and the doctor must justify the choice, obtain the patient's written informed consent and assess the effects over time. So three things go in the clinical record: the authorised indication, the one you used, and the reason why.

If you use a product for something the label does not state, the question is what to write so that you can explain it afterwards. Whether a use makes sense in a patient is your decision; here we are talking about what the sources require you to document.

What «off-label» means and where the indication is found

The authorised indication of a medicine is in the summary of product characteristics, which article 13 calls exactly that. It is not a market opinion: it lists the conditions, the patients and the doses for which the product has been authorised.

To see what it looks like, take the label approved by the American FDA for a botulinum toxin product, which our brain stores. Section 1 lists the indications one by one (overactive bladder, chronic migraine, spasticity, cervical dystonia, severe axillary hyperhidrosis, blepharospasm, strabismus) and then a block of «limitations of use»: where safety and efficacy have not been established. Further on there are the warnings, and in between an item entitled, in substance, serious adverse reactions in unapproved use. In the boxed warning on the distant spread of the toxin's effect, it states that cases have been reported both in the approved indications and in unapproved uses.

Two caveats about the example. It is the American label of a product, in the version for therapeutic indications, and not the label of the product you use in Italy. And it does not serve to say what is or is not off-label for a product you use in your practice: for that, read the summary of product characteristics of that product. It serves to show where the boundary lies and how detailed it is.

What the doctor must say and document

Three rules must be put together.

The Code, article 13. Justify, obtain written consent, assess the effects over time. It is the text that gives the three items of the clinical record.

Italian Law 219/2017. Article 1 (opens in a new tab) requires information on the benefits, risks and alternatives of the treatment, and documented consent that goes into the clinical record. An off-label use has by definition less supporting data: the information on risks and alternatives is the one the patient will not find in the product leaflet.

The Code, articles 33 and 35. The information must be understandable and exhaustive (33), and the consent is obtained by the doctor, without delegation (35). If the receptionist has the off-label form signed without you having explained it, your signature on the sheet says less than you think.

The page on legal protection for off-label use gathers the other rules on the subject.

Assessing the effects over time and reporting

The last part of article 13 is the one that gets forgotten: the doctor «assesses the effects over time». It is not a generic invitation. It means that the clinical record must contain a planned check, with a date, and then the outcome of that check, written down. The same article also states that the doctor must promptly report to the competent authority adverse or suspected adverse reactions to medicines and unfavourable or suspected events arising from the use of biomedical devices. An off-label use without a written check leaves the clinical record half done: it says what you did, and is silent on how it went.

Guidelines and good practice

Italian Law 24/2017 (opens in a new tab), article 5, states that anyone practising a health profession follows, save for the specific features of the individual case, the recommendations of the guidelines published in accordance with the law (drawn up by bodies, institutions and scientific societies entered in a specific list); in their absence, good clinical and care practice. For off-label use this means that the justification under article 13 is not just a sentence: if you have a guideline or a publication, you cite it. In the clinical record a reference is worth more than a generic formula.

Article 7 of the same law recalls another point: the healthcare facility is liable for the conduct, intentional or negligent, of the professionals it uses, and the professional is liable for his own work. The note on off-label use remains yours.

A medical device used outside its intended purpose

The rule article 13 deals with concerns medicines. Fillers, for example, are products under Annex XVI of the medical devices regulation, and not medicines.

In Regulation (EU) 2017/745 the «intended purpose» (opens in a new tab) (article 2, point 12) is the use for which a device is intended according to the indications given by the manufacturer on the label, in the instructions for use and in the sales materials. The word is different («intended purpose», not «indication»), and article 13 of the Code does not mention it. What must be written for a device used outside its declared intended purpose is a question for the practice's lawyer. What you can do, in any case, is note the intended purpose declared by the manufacturer, the one you used it for and the reason: a short note today is more useful than a reconstruction in two years' time.

How it is recorded, in Fibonacci

In the record of a session there is an «off-label» box. It is ticked when the product is used outside the authorised indications, and it matters: the use is lawful, but requires specific information, and having recorded it is what allows you to demonstrate it. The box marks the fact. The justification, the scientific reference and what you told the patient are written by you, in the session notes.

An example of a line, with fictitious data:

Session of 14/09. Example patient. Product X, authorised indication: Y. Use at site Z: off-label. Reason: [your clinical assessment]. Reference: [guideline or publication cited]. Informed of the limits of the available data, of the specific risks and of the alternatives. Written consent signed on 14/09. Check planned for [date], to assess the effects.

The square brackets are the work no software does in your place.

A checklist

  • I have read the product's summary of product characteristics and I know what the authorised indication is
  • In the clinical record I have written that one, and the one I used
  • The clinical justification is written in my own words
  • I have cited the guideline or publication I rely on
  • The patient received information on risks and alternatives, from me
  • The written consent names the off-label use
  • The off-label box of the session is ticked
  • I have set when I will assess the effects

What Fibonacci does for this

This is how it looks in Fibonacci, with sample data:

Sessions with product and batch in Fibonacci, with sample data

Sources

  1. FNOMCeO Code of Medical Ethics, articles 13, 33 and 35 (opens in a new tab)
  2. Italian Law 8 March 2017, no. 24 (Gelli-Bianco), articles 5 and 7 (Normattiva) (opens in a new tab)
  3. Italian Law 22 December 2017, no. 219, article 1 (Normattiva) (opens in a new tab)
  4. FDA-approved BOTOX (onabotulinumtoxinA) label, DailyMed (opens in a new tab)
  5. Regulation (EU) 2017/745 (MDR), Article 2, point 12 (opens in a new tab)

These articles explain what regulations and guidelines require and what is documented in the medical record. They are not legal or tax advice on your situation and do not say how to treat a patient.

Try Fibonacci in your practice for 15 days, no credit card needed

Within one working day we call you: together we set up your practice and import your data.

Try it free

Read next

All articles